Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval symbols : NVO save search
Awiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities
Published: 2024-03-21 (Crawled : 16:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -1.04%
H: 1.6%
C: 0.64%
awiqli approval treatment diabetes insulin
Global Hemophilia Research Analysis Report 2023: A $21.07 Billion Market by 2030 - Approval of Gene Therapies and Monoclonal Antibodies Fueling Growth
Published: 2023-08-16 (Crawled : 01:00) - prnewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.26%
H: 0.26%
C: -0.46%
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -0.71%
H: 1.45%
C: 0.97%
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -0.3%
H: 1.35%
C: 0.05%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.33%
H: 0.0%
C: 0.0%
report approval research global growth market
Novo Nordisk announces FDA approval of label update for Rybelsus® (semaglutide) allowing use as a first-line option for adults with type 2 diabetes
Published: 2023-01-13 (Crawled : 02:00) - prnewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: 1.51%
H: 0.89%
C: 0.5%
rybelsus fda label approval diabetes update
Novo Nordisk receives FDA approval of higher-dose Ozempic® 2 mg providing increased glycemic control for adults with type 2 diabetes
Published: 2022-03-28 (Crawled : 23:00) - prnewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: 2.86%
H: 0.47%
C: -0.72%
ozempic fda control approval diabetes
Ozempic® 2.0 mg recommended for approval for the treatment of type 2 diabetes by the European Medicines Agency
Published: 2021-11-12 (Crawled : 11:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
diabetes treatment europe approval
Wegovy™ recommended for approval for the treatment of obesity by the European regulatory authorities
Published: 2021-11-11 (Crawled : 17:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
treatment obesity europe approval
Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval
Published: 2021-05-28 (Crawled : 15:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -0.01%
H: 0.93%
C: 0.11%
diabetes treatment approval
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.